Deutsche Bank’s Vertex Pharmaceuticals VRTX Stock Holding History

Deutsche Bank’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-31,003	Closed	-$3.68M	–	5998
2014 Q4	$3.68M	Buy	31,003 +42	+0.1%	+$4.73K	﹤0.01%	2204
2014 Q3	$3.48M	Buy	30,961 +4,595	+17%	+$437K	﹤0.01%	2094
2014 Q2	$2.5M	Buy	26,366 +14,303	+119%	+$1M	﹤0.01%	2298
2014 Q1	$102K	Sell	12,063 -500	-4%	-$39.6K	﹤0.01%	4230
2013 Q4	$116K	Buy	12,563 +3,152	+33%	+$220K	﹤0.01%	3989
2013 Q3	$81K	Buy	9,411 +278	+3%	+$22.1K	﹤0.01%	4516
2013 Q2	$33K	Buy	+9,133	New	+$673K	﹤0.01%	4645

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Deutsche Bank's VRTX Position: Q1 2026 in Review

Deutsche Bank reduced its Vertex Pharmaceuticals (VRTX) stake by 13% in Q1 2026, selling an estimated $108M and leaving 1,537,736 shares worth $687M. The position accounts for 0.23% of the portfolio, ranked #92.

Deutsche Bank first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $802M in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Deutsche Bank held 1,537,736 shares of Vertex Pharmaceuticals worth $687M as of Q1 2026.
Deutsche Bank sold 231,145 Vertex Pharmaceuticals shares in Q1 2026, an estimated $108M.
Vertex Pharmaceuticals made up 0.23% of Deutsche Bank's portfolio in Q1 2026, its #92 holding.
Deutsche Bank first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
Deutsche Bank's Vertex Pharmaceuticals position peaked at $802M in Q4 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.